A recent study revealed that diabetes drugs called SGLT2 inhibitors may reduce the risk of dementia and Parkinson’s disease. The study involved 358,862 participants in South Korea who started diabetes medication between 2014 and 2019. Researchers found that those taking SGLT2 inhibitors had a 20% reduced risk of Alzheimer’s disease, a 20% reduced risk of Parkinson’s disease, and a 30% reduced risk of vascular dementia. The study suggests that SGLT2 inhibitors could potentially offer some protection against these neurodegenerative diseases. However, more research is needed to validate these findings in the long term.
Source link
Study Identifies Class Of Diabetes Drugs That Cuts Risk Of Dementia, Parkinson’s Disease
